Tailored Life Sciences Insurance

Through appointed retail and wholesale brokers, our industry specialists offer comprehensive life sciences insurance solutions globally.














Feature descriptions are summaries for discussion purposes only and do not modify any policy.
Coverage is determined by the policy terms, conditions, and exclusions as issued and applicable law.

Life Sciences Insurance Life Sciences Insurance

Insurance Solutions By Life Sciences Specialists

In true partnership with our agents, we offer the following life sciences insurance solutions, customized to the needs of your clients. 

Primary Liability

Primary Liability

Through our LS Prime® and LS Prime® Advantage options, primary insurance coverage is offered as an admitted or non-admitted primary liability insurance solution. 

Excess Liability

Excess Liability

Excess liability coverage of up to $15 million is available to protect a policyholder against unforeseeable catastrophic liability judgments.

Package

Package

Your comprehensive solution, our admitted package product provides premises operations, property, commercial auto, workers compensation, crime, and umbrella coverage.

Multinational

Multinational

Addressing localized needs of customers in more than 90 countries around the world, we offer an integrated global solution through our LS Prime® specialty including Foreign Clinical Trials, Local Products policy placements and Local Admitted Package policies.

Why Berkley Life Sciences

Learn More About Us
Learn More About Us

Helpful Links

-

Partner With Us

Partner With Us

Interested in becoming a Berkley Life Sciences appointed agency? Contact us.

Find an Agent

Find an Agent

Ready for an insurance solution that is tailored to your life sciences business by life sciences specialists? Find an agent. 

Approved State Filings

Approved State Filings

Explore our approved state filings for our admitted products. Our non-admitted coverages are available in all 50 states.

All states except the following are approved: Alaska, Arkansas, California, Hawaii, Kansas, Minnesota, Montana, New Mexico, New York, North Dakota, Oklahoma, South Dakota, Vermont, Washington State, Wyoming

The Latest in Life Science

Digital Health FDA TEMPO

FDA’s 2026 Guidance Expands Pathway for Low-Risk Digital Health Products—But Caution Remains Essential

The new year has brought notable changes on the regulatory front for life science companies seeking to expand their portfolio of digital health products. In January 2026, the U.S. Food & Drug Administration (FDA) published updated guidance documents addressing two broad product categories: (1) low-risk digital health devices for general wellness use; and (2) clinical decision support (CDS) software.

Semaglutide Compounding

GLP-1 Compounding: When Innovation May Mean Liability

As previously reported on our blog, the rise of compounded GLP-1 medications has sparked both excitement and concern across the healthcare and legal landscapes. As demand for weight-loss treatments increases, some pharmacies have begun offering compounded versions of popular drugs like semaglutide and tirzepatide.

Opens email application

Opens in new tab